Why the study?
Most AF recommendations focus on rate or rhythm control and thromboembolism prevention, but very few studies have addressed unmasking coexistent CAD and how treating underlying ischemia impacts AF burden.
This review emphasizes the intricate pathophysiological relationship between AF and CAD, advocating for a holistic management strategy that targets both conditions simultaneously rather than in isolation.
endothelial dysfunctional and inflammation and together with enhanced thrombogenicity and hypercoagulability contribute to micro and macrothrombi throughout cardiovascular system. In a nutshell, the two form a vicious cycle wherein one disease promotes the other. Most AF recommendations focuses on rate/rhythm control and prevention of thromboembolism. Very few studies have discussed the importance of unmasking coexistent CAD and how the treatment of underlying ischemia will impact the burden of AF in these patients. Inflammation and endothelial dysfunction remain central to both disease processes and form a handsome therapeutic target in the management of the two diseases. The relationship between AF and CAD is complex and much more than mere coincidence. The two diseases share common risk factor and pathophysiology. Hence, it is impractical to treat them in isolation. Accordingly, we share the implications of managing underlying ischemia and inflammation to positively impact and improve quality of life among AF patients.
No takes yet. Share an insight, caveat, or question.
Batta et al. (2023) conducted a review in Atrial fibrillation and coronary artery disease. Integrated management of coexistent AF and CAD was evaluated.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: